Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund

Executive Summary

Public biopharma offerings gained momentum, including four IPOs during the last week of June, as US investors looked kindly on the sector ahead of July 4 celebrations. Also, VC investment continued unabated as Atlas Venture closed a new $350m fund.

Advertisement

Related Content

Mixed Data For Bluebird's LentiGlobin, But Conditional Approval On The Cards
Melinta To Launch First Commercial Drug Baxdela Independently
Clovis's Rubraca Leapfrogs Rivals In Ovarian Cancer As ARIEL3 Hits
China Investment Roundup: Strategic Overseas Moves Target Product Acquisitions
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules
VC Roundup: Magenta Raises $48.5m To Improve Stem Cell Transplants
Value Unlocked: BMS Buying Padlock For Up To $600m
Startups Stand Out As 13 Biotechs Raise More Than $409m
NightstaRx Boasts Advantage Over Spark In Inherited Retinal Disease

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel